

Specimen Collected: 20-Mar-23 14:26

Drug Panel 7A, Urn, Scrn w/Rflx to Conf | Received: 23-Mar-23 14:29 | Report/Verified: 23-Mar-23 15:22

Procedure	Result	Units	Reference Interval
Creatinine, Urine	194.0	mg/dL	[20.0-400.0]
Alcohol, Urn, Screen	Negative	mg/dL	[Cutoff 40]
Amphetamines, Urn, Screen	Positive	ng/mL	[Cutoff 300]
Barbiturates, Urn, Screen	Negative	ng/mL	[Cutoff 200]
Benzodiazepines, Urn, Screen	Negative	ng/mL	[Cutoff 200]
Cocaine, Urn, Screen	Negative	ng/mL	[Cutoff 150]
Opiates, Urn, Screen	Negative	ng/mL	[Cutoff 300]
Phencyclidine, Urn, Screen	Negative	ng/mL	[Cutoff 25]
THC, Urn, Screen	Negative	ng/mL	[Cutoff 50]
CDASU 7A Comments	See Note ⁱ¹		

Amphetamines, Urn, Quant | Received: 23-Mar-23 14:29 | Report/Verified: 23-Mar-23 15:23

Procedure	Result	Units	Reference Interval
Amphetamine, Urn, Quant	>5000 ^{f1 i2}	ng/mL	
MDA, Urn, Quant	<200	ng/mL	
MDEA, Urn, Quant	<200	ng/mL	
MDMA, Urn, Quant	<200	ng/mL	
Methamphetamine, Urn, Quant	>10000 ^{f2}	ng/mL	
Phentermine, Urn, Quant	<200	ng/mL	

Result Footnote

f1: Amphetamine, Urn, Quant

Consistent with use of a drug containing amphetamine. May also reflect metabolism of methamphetamine, when methamphetamine is present. Amphetamine and methamphetamine exist in d- and l-isomeric forms. These forms are not distinguished by this test. Isomeric separation is available separately for an additional charge.

f2: Methamphetamine, Urn, Quant

Consistent with use of a drug containing methamphetamine. Methamphetamine is metabolized to amphetamine. Amphetamine and methamphetamine exist in d- and l-isomeric forms. These forms are not distinguished by this test. Isomeric separation is available separately for an additional charge.

Test Information

i1: CDASU 7A Comments

INTERPRETIVE INFORMATION: Drug Panel 7A, Urn, Scrn w/Rflx to Conf

The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration at which the screening test can detect a drug or metabolite varies within a drug class. Specimens for which drugs or drug classes are detected by the screen are reflexed to a second, more specific technology (GC/MS, GC/FID, and/or LC-MS/MS). The concentration value must be greater than or equal to

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 23-079-900243

Report Request ID: 17731671

Printed: 23-Mar-23 16:01

Page 1 of 2

Test Information

i1: CDASU 7A Comments
the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.

For medical purposes only; not valid for forensic use.

Oxycodone results are reported with the opiates results. MDMA results are reported with the amphetamines results.

i2: Amphetamine, Urn, Quant
INTERPRETIVE INFORMATION: Amphetamines, Urine,
Quantitative

Methodology: Quantitative Liquid Chromatography-Tandem Mass Spectrometry

Positive cutoff: 200 ng/mL unless specified below:

Amphetamine 50 ng/mL

For medical purposes only; not valid for forensic use.

The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 23-079-900243

Report Request ID: 17731671

Printed: 23-Mar-23 16:01